Patel Sagar, Bettag Joseph, Baral Nikita, Tauseef Abubakar, Jabbar Ali Bin Abdul
Creighton University School of Medicine, Phoenix, Arizona.
Creighton University School of Medicine, Omaha, Nebraska.
ACR Open Rheumatol. 2025 Jun;7(6):e70057. doi: 10.1002/acr2.70057.
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with variable mortality rates among different demographic groups. Despite treatment advancements, disparities in SLE outcomes continue to exist.
This study used the Centers for Disease Control and Prevention Wide-ranging Online Data for Epidemiologic Research database data from 1999 to 2022 to examine SLE-related mortality trends. Age-adjusted mortality rates (AAMRs) were calculated, and Joinpoint regression was employed to evaluate annual percentage changes (APCs) over time for mortality stratified by gender, race, census regions, age groups, and states.
A total of 52,430 SLE-related deaths occurred over the study period. The AAMR decreased from 1 per 100,000 in 1999 to 0.78 per 100,000 in 2022. The AAMR of SLE-related deaths decreased by 21% from 1 in 1999 to 0.79 in 2019 (average APC -1.23, 95% confidence interval -1.48 to -0.96). It increased by 21.52% from 0.79 in 2019 to 0.96 in 2021. From 1999 to 2019, men decreased by 33.33% compared to 21.02% in women, whereas women saw a more considerable increase from 2019 to 2021. Non-Hispanic Asians or Pacific Islander patients saw the most decrease (-43.37%), followed by Hispanic patients (-40.60%), non-Hispanic African American patients (-25.83%), and non-Hispanic White patients (-21.43%). Hispanic patients saw the most significant increase from 2019 to 2021, whereas non-Hispanic African American patients had the highest AAMR among all racial and ethnic subgroups from 1999 to 2022. The South had the highest AAMR throughout the study period among census regions.
Persistent disparities have been observed in SLE-related mortality rates from 1999 to 2022, with female sex, non-Hispanic African American race, and southern region being disproportionately impacted by worse mortality outcomes.
系统性红斑狼疮(SLE)是一种慢性自身免疫性疾病,不同人群的死亡率有所不同。尽管治疗取得了进展,但SLE的治疗结果差异仍然存在。
本研究使用疾病控制与预防中心1999年至2022年的广泛在线流行病学研究数据库数据,以研究与SLE相关的死亡率趋势。计算年龄调整死亡率(AAMR),并采用Joinpoint回归评估按性别、种族、人口普查区域、年龄组和州分层的死亡率随时间的年度百分比变化(APC)。
在研究期间,共发生了52430例与SLE相关的死亡。AAMR从1999年的每10万人1例降至2022年的每10万人0.78例。与SLE相关的死亡的AAMR从1999年的1例降至2019年的0.79例,下降了21%(平均APC -1.23,95%置信区间-1.48至-0.96)。从2019年的0.79例增至2021年的0.96例,增长了21.52%。从1999年到2019年,男性下降了33.33%,而女性下降了21.02%,而从2019年到2021年,女性的增长更为显著。非西班牙裔亚洲人或太平洋岛民患者下降最多(-43.37%),其次是西班牙裔患者(-40.60%)、非西班牙裔非裔美国患者(-25.83%)和非西班牙裔白人患者(-21.43%)。从2019年到2021年,西班牙裔患者增长最为显著,而非西班牙裔非裔美国患者在1999年至2022年期间在所有种族和族裔亚组中的AAMR最高。在人口普查区域中,南部在整个研究期间的AAMR最高。
1999年至2022年期间,在与SLE相关的死亡率方面观察到持续存在的差异,女性、非西班牙裔非裔美国人种族和南部地区受到更差死亡率结果的影响尤为严重。